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ABSTRACT   
In Alzheimer’s disease (AD), a single nucleotide polymorphism in the gene encoding brain-
derived neurotrophic factor (BDNFVal66Met) is associated with worse impact of primary AD 
pathology (beta-amyloid, Aβ) on neurodegeneration and cognitive decline, rendering 
BDNFVal66Met an important modulating factor of cognitive impairment in AD. However, the 
effect of BDNFVal66Met on functional networks that may underlie cognitive impairment in AD 
is poorly understood. Using a cross-validation approach, we first explored in subjects with 
autosomal dominant AD (ADAD) from the Dominantly Inherited Alzheimer Network 
(DIAN) the effect of BDNFVal66Met on resting-state fMRI assessed functional networks. In 
seed-based connectivity analysis of six major large-scale networks, we found a stronger 
decrease of hippocampus (seed) to medial-frontal connectivity in the BDNFVal66Met-carriers 
compared to BDNFVal-homozogytes. BDNFVal66Met was not associated with connectivity in any 
other networks. Next, we tested whether the finding of more pronounced decrease in 
hippocampal-medial-frontal connectivity in BDNFVal66Met could be also found in elderly 
subjects with sporadically occurring Aβ, including a group with subjective cognitive decline 
(N=149, FACEHBI study) and a group ranging from preclinical to AD dementia (N=114, 
DELCODE study). In both of these independently recruited groups, BDNFVal66Met was 
associated with a stronger effect of more abnormal Aβ-levels (assessed by biofluid-assay or 
amyloid-PET) on hippocampal-medial-frontal connectivity decreases, controlled for 
hippocampus volume and other confounds. Lower hippocampal-medial-frontal connectivity 
was associated with lower global cognitive performance in the DIAN and DELCODE studies. 
Together these results suggest that BDNFVal66Met is selectively associated with a higher 
vulnerability of hippocampus-frontal connectivity to primary AD pathology, resulting in 
greater AD-related cognitive impairment.     
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INTRODUCTION   
Brain derived neurotrophic factor (BDNF) is part of the neurotrophin family, playing a critical 
role in synaptic plasticity and repair throughout the lifespan.1-3 BDNF is expressed beyond the 
neocortex particularly in the hippocampus,4 where BDNF is essential for long-term 
potentiation (LTP) underlying hippocampus-related memory.1, 3, 5 Hippocampus-dependent 
memory impairment is a key feature of Alzheimer’s disease (AD), where beta-amyloid (Aβ) 
and tau are hallmark pathologies affecting the hippocampus early in AD.6-8 Post-mortem 
studies showed decreased hippocampal BDNF-levels among other brain regions in patients 
with AD dementia or mild cognitive impairment (MCI).9, 10 These observations raise the 
important question whether altered BDNF-levels modulate the impact of AD pathology on 
brain function. Preclinical research in transgenic AD mouse models showed that genetic 
delivery or overexpression of BDNF improved hippocampus LTP11, 12 and alleviated the 
impact of amyloid or tau pathology on cell loss and memory,12, 13 suggesting protective 
BDNF-effects in AD. However, in humans the role of BDNF in modulating the impact of AD 
pathology is not well understood.  
A single nucleotide polymorphism (SNP) (rs6265) resulting in the substitution of Valine by 
Methionine in the BDNF pro-domain (i.e. BDNFVal66Met) leads to reduced synaptic BDNF 
release.14, 15 Because BDNFVal66Met shows a relatively high prevalence ranging from 29% in 
European to 72% in Asian countries,16 BDNFVal66Met may constitute a genetic factor that 
modifies functional brain alterations in a substantial portion of AD subjects.17-21 Although 
neuroimaging studies in AD showed only small BDNFVal66Met–effects on hippocampal 
volume,22, 23 several studies have found BDNFVal66Met-related reductions in hippocampal FDG-
PET metabolism and stronger memory impairment in both autosomal dominant and sporadic 
AD.17, 19-21 In line with the results in transgenic AD mouse models,12, 13 these results suggest 
that BDNFVal66Met influences in particular the impact of AD pathology on hippocampal 
function and memory. Yet, the impact of BDNFVal66Met at the level of functional networks that 
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support cognitive function is unknown. Thus, our major aim was to assess whether 
BDNFVal66Met moderates the impact of AD pathology on functional connectivity within major 
networks and associated cognitive impairment in AD.  
The brain is composed of major large-scale functional networks that become engaged during 
cognitive tasks. Resting-state fMRI studies assessing the integrity of these networks in AD 
have shown reduced connectivity between the hippocampus and medial-frontal and posterior-
parietal regions of the default-mode network (DMN).24-28 Higher Aβ-levels were associated 
with lower hippocampus connectivity underlying memory impairment in preclinical and 
prodromal AD patients.29, 30 Here, we hypothesized that in BDNFVal66Met carriers, the impact 
of higher Aβ pathology on hippocampus connectivity and memory impairment is worse 
compared to homozygous BDNFVal-carriers. We tested this hypothesis in three independently 
recruited samples of subjects with either genetically caused AD or biomarker evidence of Aβ. 
In a discovery sample of 115 mutation-carriers with autosomal dominant AD (ADAD) and 91 
familial non-carrier controls from the Dominantly Inherited Alzheimer Network (DIAN),31 
we explored in which functional network BDNFVal66Met-carriers showed altered connectivity 
compared to homozygous BDNFVal-carriers.  
For our hypothesis-driven analysis we assessed connectivity alterations in the hippocampal 
network, and for exploratory purposes, in a set of other major functional networks (i.e. DMN, 
dorsal attention [DAN], salience [SAL], fronto-parietal control [CON]) that are part of the 
canonical set of resting-state networks associated with higher cognitive function and 
previously found altered in AD.32, 33 We specifically conducted the discovery analyses in 
ADAD, since the study design of DIAN allows to examine the effect of BDNFVal66Met on 
connectivity changes in genetically caused AD where aging-related comorbidities such as 
cerebrovascular changes are unlikely. Based on the results on the association between 
BDNFVal66Met and functional network changes in ADAD, confirmatory analyses were 
subsequently conducted in elderly subjects with biomarker evidence of sporadic AD, 
Franzmeier et al. 
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including 149 subjects with subjective cognitive decline (SCD) from the Spanish FACEHBI 
study34 and in 114 subjects ranging from cognitively normal to AD dementia assessed within 
the German DELCODE study.35 The inclusion of these additional samples with sporadic AD 
pathophysiology provided the opportunity to test whether any effects of BDNFVal66Met on 
connectivity can be generalized towards the more common age-related form of accumulating 
AD pathology in elderly subjects. Since BDNFVal66Met has been previously associated with 
greater cognitive impairment in both autosomal dominant and sporadic AD,17, 19, 20 we tested 
in a last step whether any observed BDNFVal66Met-related functional network alterations are 
associated with worse global cognition and episodic memory. 
  






115 carriers of ADAD-causing mutations in genes PSEN1 (n=82) & PSEN2 (n=12) or APP 
(n=21), and 91 non-carrier (NC) siblings were included from DIAN data freeze 10.31 Beyond 
DIAN inclusion criteria, the current study required availability of BDNFVal66Met genotype, 
resting-state fMRI, T1-structural MRI and cognitive assessments. No selection bias (i.e. 
demographic differences between the included subjects and excluded subjects) was found 
(p>0.05) for age, gender or education. As a marker of AD severity, we applied the estimated 
years from symptom onset (EYO), defined as the difference between a participants age at 
examination and the parental age of symptom onset for ADAD mutation carriers, as described 
previously.36-38 As an additional marker of amyloid pathology, we employed global PiB-PET 
SUVR scores (normalized to the whole cerebellum, available in a subsample of 100 mutation 
carriers and 87 non-carriers) provided by the DIAN core, where subjects were binarized as 
Aβ+ at a SUVR threshold >1.31 following recommendations by the DIAN core. For details 
on PiB-PET assessment in DIAN, please refer to a previous publication.39 BDNFVal66Met-
genotyping was performed on whole-blood samples using the Infinium HumanExomeCore 
V1.0 Beadchip (Illumina, Inc.) at Washington University. Each participant provided written 
informed consent. Local ethical approval was obtained at each DIAN site. 
 
DELCODE: 
114 older adults (>60 years) were included from the German multicenter DELCODE cohort 
on sporadic AD (data freeze 1, N=366).35 Beyond DELCODE inclusion criteria, subjects had 
to have available BDNFVal66Met data, resting-state fMRI and T1-structural MRI, cerebrospinal 
fluid (CSF)-assessed Aβ-levels (Aβ42/40 ratio) and cognitive assessments. Testing for 
selection bias yielded no significant (p>0.05) differences between the selected and excluded 
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subjects for age, gender and education. Subjects met classification criteria for cognitively 
normal (CN), SCD (i.e. normal cognitive performance and subjective cognitive decline 
between the last 6 months and 5 years), MCI or AD dementia, following previously described 
procedures.35, 37 Continuous CSF Aβ42/40-ratio levels, i.e. a close correlate of brain Aβ-
levels,40 were used as a marker of AD pathology. For descriptive purposes Aβ-positivity was 
defined as CSF Aβ42/40<0.1, following pre-established cut-points41 used within 
DELCODE.37 BDNFVal66Met-genotyping was performed on whole-blood samples using 
commercially available TaqMan probes (ThermoFischer). All subjects provided written 
informed consent, local ethical approval was obtained at each DELCODE site. 
  
FACEHBI: 
149 older adults (>50 years) were included from the Spanish monocentric FACEHBI cohort 
(n=214) collected at the Fundació ACE Alzheimer Treatment and Research Center in 
Barcelona. All subjects met research criteria for SCD as defined by the FACEHBI core (i.e. 
coexistence of subjective cognitive complaints defined as a score>7 on the memory failures in 
everyday life questionnaire,42 and normal performance in a comprehensive 
neuropsychological battery).43 For a detailed sample description and inclusion criteria please 
see a previous publication.34 For the current study, subjects were included based on 
availability of BDNFVal66Met genotype, resting-state fMRI, T1-structural MRI, 
18[F]-
Florbetaben amyloid-PET and cognitive data. No significant differences (p>0.05) were found 
in age, gender or education between the selected and excluded subjects. AD pathology was 
assessed using continuous measures of global 18[F]-Florbetaben PET SUVR scores, that were 
additionally stratified into Aβ-positive/negative for descriptive purposes, using a standard 
uptake value ratio (SUVR) threshold >1.45, following previous recommendations.44 The 
assessment of global Aβ-PET SUVR has been conducted by the FACEHBI core and was 
described in detail previously.45 The BDNFVal66Met genotype was extracted from GWAS data 
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performed on whole-blood samples with the Illumina Infinium Omni Express Exome-8v1.3 
chip. All subjects provided written informed consent, ethical approval was obtained by the 
FACEHBI principal investigators. 
  
Neuropsychology 
As a primary measure of cognition, we used the Mini-Mental State Exam (MMSE)46 which 
was consistently available in all samples, thus facilitating across cohort comparability. As a 
secondary measure of cognition, we used episodic memory as assessed by the delayed recall 
score of the Wechsler logical memory scale,47 which was available in DIAN and DELCODE 
sample but not in FACEHBI.  
 
MRI acquisition 
All MRI scans were recorded on 3T scanners for DIAN and DELCODE, and a 1.5T scanner 
for FACEHBI. Within the multicenter studies DIAN or DELCODE, scanning protocols were 
harmonized across participating sites for each study. Here, we included resting-state fMRI 
and high-resolution T1-structural MRI scans. Detailed sequence parameters can be found in 
supplementary table 1.  
 
Preprocessing of structural and resting-state fMRI 
The same pre-established SPM12-based pipeline previously described by us,37, 48, 49 including 
motion correction, nuisance regression (motion, white-matter & CSF), censoring of high-
motion frames, spatial normalization and smoothing was applied to each cohort (DIAN, 
DELCODE, FACEHBI) separately so no data was pooled across cohorts during the entire 
analyses. For details on MRI preprocessing please see supplementary methods. 
 
 




Assessment of seed-based connectivity 
We used a seed-based connectivity approach previously described by us37, 48, 49 in order to 
generate subject-specific Fisher z-transformed connectivity maps of hippocampal seeds and 
canonical resting-state networks (DMN, DAN, SAL, CON) for each subject from 
preprocessed resting-state fMRI data. For details on anatomical location of seed regions of 
interest (ROIs) and network topology please see figure 1 and supplementary methods. 
 
Statistical analysis 
Within each sample, we compared baseline group differences using two-sample t-tests or 
ANOVAS (for>2 groups) for continuous measures and Chi-squared tests for categorical 
measures. We further tested BDNFVal66Met deviations from the Hardy-Weinberg Equilibrium 
within each sample. Significant seed-based connectivity in DIAN was mapped by conducting 
voxel-wise t-tests against zero on the subject-specific connectivity maps (α=0.001 & FWE-
cluster correction).  
Next, we computed the voxel-wise interaction BDNFVal66Met x EYO on seed-based 
connectivity maps in the 115 ADAD mutation-carriers (DIAN), controlling for gender, center, 
education, family affiliation and subject-specific grey matter volume of the seed-ROI that was 
extracted from spatially normalized and Jacobian-scaled grey matter images. The rationale to 
use EYO as a marker of disease severity in DIAN is that 1) EYO is a valid and reliable 
marker of global AD pathology and 2) that usage of EYO facilitates the comparability with 
previous studies in this cohort. In line with previous studies in DIAN we did not control for 
age in the model,37, 38 as age is highly correlated with EYO and may mask variance of interest 
and/or induce multicollinearity. Clusters showing a significant BDNFVal66Met x EYO 
interaction (α=0.001 & FWE-cluster correction at α=0.05) were binarized to extract subject-
specific mean connectivity values from individual connectivity maps (henceforth referred to 
Franzmeier et al. 
 
13
as BDNF-related connectivity) for later analyses. Using mean connectivity values, we further 
conducted confirmatory analyses in a subset of 100 mutation-carrier subjects with available 
global amyloid-PET SUVR levels instead of EYO, to ensure that our results were not specific 
for using EYO as a measure of ADAD severity. Specifically, we tested the interaction global 
amyloid-PET SUVR x BDNFVal66Met on connectivity, controlling for gender, center, education, 
family affiliation and grey matter volume of the respective seed ROI.  
After the discovery analysis in DIAN, cluster maps of significant EYO x BDNFVal66Met 
interactions were forward applied to the DELCODE and FACEHBI groups to extract mean 
seed ROI to cluster connectivity values for validation analysis including the interaction 
BDNFVal66Met x amyloid load on connectivity. As a measure of amyloid-load, we applied 
continuous CSF measures of the Aβ42/40 ratio for DELCODE and continuous global 
amyloid-PET SUVR scores for FACEHBI. Due to the skewed distribution of global amyloid-
PET SUVRs, the scores were Box-Cox transformed prior to analysis, after which there was no 
deviation from a normal distribution. Using separate linear models for DELCODE and 
FACEHBI, we then tested the Aβ x BDNFVal66Met two-way interaction on connectivity, 
controlling for age, gender, education, ROI grey matter volume, ApoE4-status (as well as 
center and diagnosis for DELCODE). 
We further extracted connectivity to clusters in the ADAD non-carrier group (DIAN), to 
assess potential BDNFVal66Met-related connectivity changes in relatively young subjects 
unaffected by ADAD (i.e. BDNFVal66Met x Age on connectivity, controlling for gender, family 
and grey matter volume of the respective seed ROI). The rationale for this analysis is, that the 
BDNFVal66Met genotype may also have an effect on connectivity changes in subjects unaffected 
by ADAD.  
Next, we tested separately within the ADAD subjects as well as in DELCODE and FACEHBI 
whether BDNF-related hippocampal connectivity (i.e. seed connectivity to clusters that 
showed a significant BDNFVal66Met x EYO interaction in DIAN) moderated AD-related 
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cognitive decreases. For DELCODE and FACEHBI, we used robust linear mixed-effects 
models, where we tested within each sample the two-way interaction between BDNF-related 
hippocampal-medio-frontal connectivity and amyloid on 1) episodic memory or 2) global 
cognition controlling for gender, and hippocampal volume. Due to the study design of 
DELCODE we additionally included diagnosis as a fixed effect and center as a random effect 
in the respective statistical models. MMSE values were box-cox transformed prior to analyses 
to minimize skew. For DIAN, analogous regression analyses were run using MMSE or 
episodic memory as dependent variables, testing the two-way interaction between 
hippocampal-medial-frontal connectivity and EYO, controlling for family affiliation (to 
control for shared genetic background among DIAN family members), gender and 
hippocampal volume. 
All voxel-wise analyses were computed in SPM12 and restricted to group-specific grey matter 
masks. Statistical analyses were conducted using R statistical software. Effects were 
considered significant when meeting a two-tailed alpha threshold of α=0.05.   




See table 1 for sample characteristics. Patterns of significant seed-based connectivity in the 
DIAN discovery sample are shown in Figure 1. No BDNFVal66Met deviations from Hardy-
Weinberg equilibrium were found. 
 
Discovery analysis: Interaction BDNFVal66Met x EYO on hippocampal connectivity in ADAD 
(DIAN) 
We found a significant BDNFVal66Met x EYO interaction on connectivity between the right 
hippocampus and the bilateral medial-frontal cortex (henceforth referred to right 
hippocampal-medial-frontal connectivity), a key region of the DMN (MNI: x=-2, y=33, z=14, 
t(108)=4.77, blue and purple areas in Fig. 2A). When illustrating the interaction effect using 
mean connectivity values of that cluster, BDNFVal was associated with relatively stable right 
hippocampal-medial-frontal connectivity levels across EYO, whereas BDNFVal66Met was 
associated with a decline in right hippocampal-medial-frontal connectivity across EYO (Fig. 
2B). For the left hippocampus seed ROI, the BDNFVal66Met x EYO interaction was also 
detected for the bilateral medial-frontal cortex (Fig 2E, MNI: x=4, y=49, z=-10, t(109)=3.93), 
where BDNFVal was associated with relatively preserved connectivity across EYO compared 
to BDNFVal66Met (Figure 2F). For the sake of consistency with the subsequent validation 
analyses in DELCODE and FACEHBI using continuous biomarkers of Aβ as the marker of 
AD pathology (see below), we repeated the analyses using global amyloid-PET levels instead 
of EYO as the predictor variable in a subset of 100 ADAD subjects with available PiB-PET. 
Results of the regression analysis showed a congruent interaction between global amyloid-
PET SUVR and BDNFVal66Met on both left (t(94)=3.074, β/SE=0.066/0.021, p=0.002) and 
right (t(94)=3.873, β/SE=0.083/0.021, p<0.001) hippocampus-medial-frontal connectivity. 
No Age x BDNFVal66Met interaction effects for right or left hippocampal connectivity were 
detected in the ADAD non-carriers, suggesting specificity for ADAD. Also, no main effect of 
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age on hippocampal connectivity was found in this group, suggesting that hippocampus 
connectivity remains relatively stable across age in the absence of ADAD. This view is 
further confirmed by an exploratory assessed ADAD-mutation (i.e. carriers vs. non-carriers) x 
age interaction on both left (t(196)=-2.087, b/se=-0.005/0.002, p=0.038) and right (t(196)=-
2.201, b/se=-0.006/0.003, p=0.029) hippocampus-medial-frontal connectivity, when 
controlling for gender, seed ROI volume, family and BDNFVal66Met. Here, ADAD mutation 
carriers show decreasing connectivity across age (which is highly correlated with EYO) while 
non-carriers remain relatively stable. These results suggest that the hippocampus-medial-
frontal connectivity decreases as observed in the ADAD group are driven by AD pathology 
and do not reflect normal age-related connectivity changes.   
In addition, none of the other resting-state networks (DMN, DAN, SAL, CON) showed a 
significant BDNFVal66Met x EYO interaction, both in ADAD mutation carriers and non-carriers 
(where we used age instead of EYO). 
 
Validation analyses: BDNFVal66Met and hippocampal connectivity in subjects with sporadic 
Aβ pathology (DELCODE and FACEHBI). 
To validate our findings of the association between BDNFVal66Met and hippocampal-medial-
frontal connectivity in ADAD, we assessed the interaction BDNFVal66Met x Aβ on 
hippocampus-medial-frontal connectivity (Figures 2A&E) in the independent DELCODE and 
FACEHBI samples. Here, we employed Aβ-levels to assess AD severity, since Aβ is the 
defining feature of sporadic AD pathology in the mostly non-demented DELCODE and 
FACEHBI subjects.  
By considering the clinical spectrum of CN, SCD, MCI, and AD dementia in DELCODE, we 
found a significant BDNFVal66Met x CSF Aβ42/40 interaction on both right hippocampal-
medial-frontal (β/SE=-0.404/0.179, p=0.026; Figure 2C) and left hippocampal-medial-frontal 
connectivity (β/SE=-0.355/0.169, p=0.037; Figure 2G), where BDNFVal was associated with 
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more stable connectivity across a decreasing CSF Aβ42/40 ratio compared to BDNFVal66Met. In 
FACEHBI (SCD subjects), significant BDNFVal66Met x global amyloid-PET SUVR 
interactions were observed on right hippocampal-medial-frontal (β/SE=0.301/0.170, p=0.039; 
Figure 2D) and left hippocampal-medial-frontal connectivity (β/SE=0.333/0.195, p=0.045; 
Figure 2H). In exploratory analyses, no BDNFVal66Met x global amyloid-PET SUVR 
interactions were found for any of the other functional networks in both DELCODE or 
FACEHBI. These results suggest congruent effects of BDNFVal66Met on hippocampal 
connectivity in all three samples. Regression results are summarized in table 2. 
 
BDNFVal66Met-related hippocampal-medial-frontal connectivity moderates the effect of AD-
severity on cognition   
We next tested whether BDNF-related hippocampus-medial-frontal connectivity was 
associated with cognition. In DIAN, ADAD mutation carriers showed for both right and left 
hippocampal-medial-frontal connectivity (i.e. Fig 2A&E) a significant two-way interaction 
with EYO on MMSE, when controlling for gender, education, family affiliation, respective 
hippocampal volume and center (right: β/SE=0.202/0.047, p<0.001, left: β/SE=0.177/0.068, 
p=0.009). As hypothesized, individuals with lower right and left hippocampal-medial-frontal 
connectivity showed steeper MMSE decreases across EYO than individuals with higher FC. 
A hippocampal-medial-frontal connectivity x EYO interaction was also detected for logical 
memory recall (right: β/SE=0.144/0.071, p=0.045, Figure 3B; left: β/SE=0.160/0.077, 
p=0.041), with worse memory impairment at lower hippocampal-medial-frontal connectivity.  
In DELCODE, we found a significant two-way interaction such that individuals with lower 
right hippocampal-medial-frontal (β/SE=-0.222/0.080, p=0.007; Figure 3C) or left 
hippocampal-medial-frontal connectivity (β/SE=-0.205/0.079, p=0.011) showed stronger 
MMSE reductions as a function of more abnormal CSF-Aβ42/40-levels, controlled for 
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diagnosis among other potentially confounding variables. All results remained consistent 
when additionally controlling for ApoE4 status. No interaction was found, however, for 
logical memory (Figure 3D, supplementary table 2). In the FACEHBI sample, no 
hippocampal-medial-frontal connectivity x global amyloid-PET SUVR two-way interaction 
effects on MMSE were found, probably due to lack of sufficient variance of cognitive 
performance in this cognitively normal SCD group.   




Our major finding, observed across three independent cohorts, was that BDNFVal66Met was 
associated with stronger AD pathology-related decreases of hippocampal-medial-frontal 
connectivity. Furthermore, we found that lower hippocampal-medial-frontal connectivity was 
associated with stronger reductions in global cognition in both ADAD and symptomatic 
sporadic AD. Thus, our results suggest that the variation in BDNFVal66Met moderates the effect 
of AD pathology on hippocampus functional connectivity. Although the moderating effects of 
BDNFVal66Met-related hippocampus connectivity on cognition were not strong in the current 
study, our results provide preliminary evidence that hippocampal-mediofrontal-connectivity 
alterations linked to BDNFVal66Met may contribute to global cognitive impairment in AD. 
In the current study, the association between BDNFVal66Met and decreased hippocampal-
medial-frontal connectivity has been observed across different samples including non-
symptomatic and symptomatic (MCI and dementia) AD stages, suggesting robust effects of 
BDNFVal66Met on regional hippocampal connectivity alterations across the AD spectrum. These 
results remained after accounting for hippocampus atrophy, suggesting that the association 
between BDNFVal66Met and hippocampal connectivity alterations cannot be fully explained by 
hippocampal neuronal loss. Strikingly, the association between BDNFVal66Met and stronger 
connectivity decreases was confined to the hippocampal networks since exploratory analyses 
of other major functional networks did not yield any significant effects. These findings are 
consistent with previous reports suggesting that BDNF-related alterations occur specifically in 
the hippocampus rather than other brain regions. In healthy subjects, BDNFVal66Met was 
associated with reduced hippocampal activation during an encoding task, but showed no 
effect on a wider task-activated cortical network.50 Furthermore, in ADAD, more pronounced 
FDG-PET hypometabolism within the hippocampus, but not precuneus, was observed in 
BDNFVal66Met-carriers compared to BDNFVal homozygotes.
20 Together, these results suggest 
that BDNFVal66Met is specifically associated with hippocampal alterations. Given that the 
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hippocampus is among the earliest regions to be affected by AD,51, 52 showing early 
connectivity decreases,32, 53 the design of the current study may have favored statistical power 
to detect BDNFVal66Met effects specifically within the hippocampus as most subjects had only 
mild AD. Strikingly, the moderating effects of BDNFVal66Met on the association between AD 
severity and hippocampal connectivity decreases were strongest in the ADAD group, as 
compared to the sporadic AD groups. This pronunciation of effects in ADAD might be due 
sample specific effects in the DIAN cohort. Thus, the effect size in the validation samples 
reflects probably a more likely approximation of the true effect size. Here, a large-scale study 
would be needed in order to conduct sensitivity analyses of any potential factors that may 
influence the observed effect size. 
Connectivity between the hippocampus and medial frontal cortex is supported anatomically 
by direct neuronal connections.54 Major mono-synaptic bidirectional connections between the 
orbitofrontal cortex and the peri- and entorhinal cortices, i.e. a major connection to the 
hippocampus, are constituted by the uncinate fasciculus as found in both post-mortem tracer 
studies and in-vivo diffusion-tensor imaging studies.55 Functional imaging studies have 
shown that hippocampal-orbitofrontal connections are part of a network that is activated 
during cognitive tasks tapping episodic56-58 and working memory.59, 60 Alterations in 
hippocampal-prefrontal connectivity have been previously associated with reduced episodic- 
or working memory in AD55, 61, 62 or psychiatric diseases including schizophrenia,63, 64 
suggesting that this anatomically supported functional network is critical for a wider range of 
cognitive abilities. We found that BDNFVal66Met-related hippocampal-medial-frontal 
connectivity was associated with greater impairment in episodic memory and global cognition 
in ADAD, and stronger associations between Aβ (as measured by CSF Aβ42/40) and 
impaired global cognition in a group covering the AD spectrum (DELCODE). However, no 
effect of BDNFVal66Met-related hippocampal-medial-frontal connectivity on the association 
between Aβ (as assessed by amyloid-PET) and global cognition was found in subjects with 
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SCD (FACEHBI). The variability of findings between studies may be due to small variability 
in cognitive performance and AD-related cognitive changes in SCD, requiring larger sample 
sizes to detect any small effects of BDNFVal66Met in cognitively normal subjects. Together, the 
current results suggest that BDNFVal66Met enhances the vulnerability of this hippocampal-
frontal memory network to the effects of Aβ and may thus worsen cognitive decline in 
symptomatic AD.  
While we caution that the current results do not provide evidence for causal effects of BDNF 
genetic variants on functional connectivity, we encourage future studies to examine the 
mechanisms that underlie the potential effects of BDNFVal66Met in AD. One possibility is that 
BDNFVal66Met is associated with disturbed BDNF secretion, since preclinical in-vitro and in-
vivo studies showed that BDNFVal66Met is associated with impaired intracellular BDNF 
trafficking, entailing decreased synaptic BDNF levels.14 Since LTP may enhance connectivity 
between neural populations detectable by fMRI65 and BDNFVal66Met-related reduced BDNF 
bioavailability impairs LTP,15 BDNFVal66Met may contribute to higher susceptibility of 
hippocampal connectivity to detrimental Aβ-effects. Note that we detected no difference 
between BDNFVal66Met carriers and BDNFVal-carriers in Aβ-biomarker levels. These findings 
are consistent with previous reports of the absence of altered BDNFVal66Met effects on CSF 
Aβ1-42 in ADAD20, 21 or sporadic AD.17, 66 These results are also in line with previous findings 
in transgenic AD mouse-models, where lentiviral BDNF-gene delivery reduced cell loss and 
improved learning performance, but did not alter Aβ-burden.13 Similarly, reduced BDNF-
levels were found in the P301L transgenic mouse model of tau pathology, where adeno-virus 
induced restoration of BDNF-levels alleviated synaptic degeneration and spatial memory 
deficits, but did not attenuate tau pathology.12 Together, these findings suggest that BDNF is 
not associated with alterations in the primary pathology itself, rather lower BDNF (as proxied 
by BDNFVal66Met) may be associated with enhanced susceptibility of hippocampus 
connectivity to the effects of AD pathology.  
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For drawing conclusions based on the current results, some caveats should be considered. We 
caution that BDNFVal66Met effects on BDNF-levels in the brain of AD patients is not clear, and 
we did not assess BDNF protein levels directly. Previous studies reported decreased brain 
BDNF mRNA levels in AD mouse models67 and AD patients10 as well as decreases of CSF-
derived BDNF-levels in AD patients, but CSF or serum BDNF-levels were not altered by 
BDNFVal66Met.
68, 69 The latter studies, however, included mostly healthy controls and only few 
MCI and AD cases, rendering the results difficult to interpret. BDNFVal66Met effects on CSF or 
serum-derived BDNF-levels in MCI and AD remain to be investigated in future studies.    
It should be acknowledged that we included a total of three different international studies 
using slightly different inclusion/exclusion criteria, MRI hardware and scanning protocols, 
which were not a priori harmonized across studies and can thus be considered a “naturalistic” 
sample of AD subjects. However, the heterogeneity in the sampling may also entail increased 
variability in the variable measurements and limited comparability. For instance, the 
FACEHBI 1.5T scanning protocol is potentially less sensitive to detect BOLD signal changes 
compared to the DIAN and DELCODE 3T scanning protocols.70 In order to enhance 
comparability between studies, we applied harmonized MRI preprocessing and analysis 
pipelines and selected uniformly available cognitive tests. Importantly, however, rather than 
pooling data across all samples, where variability of the data may hamper the estimation of 
the regression parameters, we used a cross-validation approach in order to test the robustness 
and external validity of our initial analysis in the ADAD sample. Thus, our highly consistent 
findings across cohorts reduce the likelihood of our results being driven by technical 
assessment procedures or selection criteria.    
A further potential limitation is that ADAD and sporadic AD may show slight differences in 
disease development.  While ADAD and sporadic AD share core neuropathological and 
clinical features71 and functional network changes72 (for a review, see73), several differences 
have been reported as well: Compared sporadic AD, ADAD is associated with an earlier 
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symptom onset,74 stronger striatal amyloid accumulation,75 higher likelihood of non-memory 
cognitive deficits,74 higher prevalence of psychosis and hallucinations71, spastic paraparesis 
and motor symptoms.76, 77 Given such differences between ADAD and sporadic AD, it is 
possible that our approach of  using the data from ADAD as the discovery sample may entail 
missing some BDNFVal66Met-associated brain network effects that are specific to sporadic AD. 
To address this caveat, we tested in exploratory secondary analyses the interaction effect of 
BDNFVal66Met x Aβ on each resting-state network in both the DELODE and FACEHBI 
studies. The absence of any interaction effect of the BDNFVal66Met genotype by Aβ biomarker 
levels on any network other than the hippocampal network supports the conclusion that the 
effects of BDNFVal66Met on exclusively hippocampal connectivity are consistent across 
samples, despite potential clinic-pathological differences between ADAD and sporadic AD. 
Lastly, we did not assess tau pathology in the current study. Tau deposition emerges first in 
the entorhinal cortex and hippocampus78 and has been shown to be correlated with cognitive 
performance and hippocampus connectivity in humans.79 Given previous preclinical evidence 
that BDNF may modulate the neurotoxic effects of tau,12 BDNFVal66Met may also alter the 
effect of tau on hippocampus function. Additionally, previous studies of ADAD have reported 
that BDNFVal66Met-carriers show faster CSF tau and p-tau181 increases.
21 The recent 
development of tau-PET will allow future studies to assess regional tau levels in the brain,80 
and provide an opportunity to test the potential modulating effects of BDNFVal66Met on 
hippocampus connectivity in future studies.  
 
Conclusions 
In summary, our results suggest that BDNFVal66Met is associated with increased impairment of 
hippocampal-medial-frontal connectivity cortex in the presence of AD pathology. 
Our current results are consistent with previous studies suggesting that BDNFVal66Met may 
moderate the neurotoxic effects of Aβ on hippocampal connectivity and memory impairment 
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in AD. A critical future question will be, whether beneficial effects of BDNFVal66Met show a 
disease stage-dependent peak i.e. at the preclinical, prodromal or dementia stage of AD. We 
thus encourage future studies to assess this question as soon as large enough data become 
available for each subgroup. Our results have clinical implications: BDNF-levels are 
modifiable in humans and could thus become a promising treatment target to enhance 
resilience against the impact of neurotoxic primary AD pathology.9 Alterations of 
hippocampal connectivity can be a potential outcome measure to assess the effect of BDNF-
targeting drugs in AD. Increased BDNF-levels after aerobic exercise have been observed in 
subjects with neurological disorders,81 and this may mediate the effect of exercise on 
enhanced synaptic plasticity and hippocampus-dependent learning.82 Enhancing BDNF-levels 
in the brain may thus constitute a promising secondary-preventive approach to attenuate AD-
effects on brain integrity and cognitive function.9, 83  
 
  




1. Bekinschtein P, Cammarota M, Katche C, Slipczuk L, Rossato JI, Goldin A et al. 
BDNF is essential to promote persistence of long-term memory storage. Proceedings 
of the National Academy of Sciences of the United States of America 2008; 105(7): 
2711-2716. 
 
2. Song M, Martinowich K, Lee FS. BDNF at the synapse: why location matters. Mol 
Psychiatry 2017; 22(10): 1370-1375. 
 
3. Hall J, Thomas KL, Everitt BJ. Rapid and selective induction of BDNF expression in 
the hippocampus during contextual learning. Nature neuroscience 2000; 3(6): 533-
535. 
 
4. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the 
control human brain, and in Alzheimer's disease and Parkinson's disease. Progress in 
neurobiology 2001; 63(1): 71-124. 
 
5. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and 
dysfunction. Handb Exp Pharmacol 2014; 220: 223-250. 
 
6. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early 
Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006; 27(10): 
1372-1384. 
 
Franzmeier et al. 
 
26
7. de Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology 
in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. 
Alzheimers Dement 2016; 12(6): 633-644. 
 
8. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ et al. MRI of 
hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype 
and biomarkers. Brain : a journal of neurology 2009; 132(Pt 4): 1067-1077. 
 
9. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a 
disease-modifying strategy for neurodegenerative diseases. Nature reviews 
Neuroscience 2013; 14(6): 401-416. 
 
10. Michalski B, Corrada MM, Kawas CH, Fahnestock M. Brain-derived neurotrophic 
factor and TrkB expression in the "oldest-old," the 90+ Study: correlation with 
cognitive status and levels of soluble amyloid-beta. Neurobiol Aging 2015; 36(12): 
3130-3139. 
 
11. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM et al. 
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate 
models of Alzheimer's disease. Nature medicine 2009; 15(3): 331-337. 
 
12. Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH et al. Brain-derived neurotrophic 
factor protects against tau-related neurodegeneration of Alzheimer's disease. Transl 
Psychiatry 2016; 6(10): e907. 
 
Franzmeier et al. 
 
27
13. Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E et al. Early 
BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. 
J Neurosci 2013; 33(39): 15596-15602. 
 
14. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. 
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and 
human memory and hippocampal function. Cell 2003; 112(2): 257-269. 
 
15. Hao R, Qi Y, Hou DN, Ji YY, Zheng CY, Li CY et al. BDNF val66met 
Polymorphism Impairs Hippocampal Long-Term Depression by Down-Regulation of 
5-HT3 Receptors. Front Cell Neurosci 2017; 11: 306. 
 
16. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF et al. Population 
genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 
2010; 15(8): 810-815. 
 
17. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA et al. BDNF 
Val66Met, Abeta amyloid, and cognitive decline in preclinical Alzheimer's disease. 
Neurobiology of aging 2013; 34(11): 2457-2464. 
 
18. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA et al. Effect of 
BDNF Val66Met on memory decline and hippocampal atrophy in prodromal 
Alzheimer's disease: a preliminary study. PloS one 2014; 9(1): e86498. 
 
Franzmeier et al. 
 
28
19. Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D et al. APOE 
and BDNF polymorphisms moderate amyloid beta-related cognitive decline in 
preclinical Alzheimer's disease. Mol Psychiatry 2015; 20(11): 1322-1328. 
 
20. Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL et al. BDNF 
Val66Met moderates memory impairment, hippocampal function and tau in preclinical 
autosomal dominant Alzheimer's disease. Brain : a journal of neurology 2016; 139(Pt 
10): 2766-2777. 
 
21. Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C et al. Effect 
of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. 
Ann Neurol 2018; 84(3): 424-435. 
 
22. Kambeitz JP, Bhattacharyya S, Kambeitz-Ilankovic LM, Valli I, Collier DA, McGuire 
P. Effect of BDNF val(66)met polymorphism on declarative memory and its neural 
substrate: a meta-analysis. Neuroscience and biobehavioral reviews 2012; 36(9): 
2165-2177. 
 
23. Harrisberger F, Spalek K, Smieskova R, Schmidt A, Coynel D, Milnik A et al. The 
association of the BDNF Val66Met polymorphism and the hippocampal volumes in 
healthy humans: a joint meta-analysis of published and new data. Neuroscience and 
biobehavioral reviews 2014; 42: 267-278. 
 
24. Park KH, Noh Y, Choi EJ, Kim H, Chun S, Son YD. Functional Connectivity of the 
Hippocampus in Early- and vs. Late-Onset Alzheimer's Disease. Journal of clinical 
neurology 2017; 13(4): 387-393. 




25. Allen G, Barnard H, McColl R, Hester AL, Fields JA, Weiner MF et al. Reduced 
hippocampal functional connectivity in Alzheimer disease. Arch Neurol 2007; 64(10): 
1482-1487. 
 
26. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity 
distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. 
Proceedings of the National Academy of Sciences of the United States of America 
2004; 101(13): 4637-4642. 
 
27. Tahmasian M, Pasquini L, Scherr M, Meng C, Forster S, Mulej Bratec S et al. The 
lower hippocampus global connectivity, the higher its local metabolism in Alzheimer 
disease. Neurology 2015; 84(19): 1956-1963. 
 
28. Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L et al. Selective changes 
of resting-state networks in individuals at risk for Alzheimer's disease. Proceedings of 
the National Academy of Sciences of the United States of America 2007; 104(47): 
18760-18765. 
 
29. Pasquini L, Scherr M, Tahmasian M, Meng C, Myers NE, Ortner M et al. Link 
between hippocampus' raised local and eased global intrinsic connectivity in AD. 
Alzheimers Dement 2015; 11(5): 475-484. 
 
30. La Joie R, Landeau B, Perrotin A, Bejanin A, Egret S, Pelerin A et al. Intrinsic 
connectivity identifies the hippocampus as a main crossroad between Alzheimer's and 
semantic dementia-targeted networks. Neuron 2014; 81(6): 1417-1428. 




31. Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ et al. 
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. 
Alzheimers Res Ther 2013; 5(5): 48. 
 
32. Jones DT, Knopman DS, Gunter JL, Graff-Radford J, Vemuri P, Boeve BF et al. 
Cascading network failure across the Alzheimer's disease spectrum. Brain 2016; 
139(Pt 2): 547-562. 
 
33. Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C et al. 
Functional connectivity in autosomal dominant and late-onset Alzheimer disease. 
JAMA neurology 2014; 71(9): 1111-1122. 
 
34. Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour C, 
Valero S et al. FACEHBI: A Prospective Study of Risk Factors, Biomarkers and 
Cognition in a Cohort of Individuals with Subjective Cognitive Decline. Study 
Rationale and Research Protocols. J Prev Alzheimers Dis 2017; 4(2): 100-108. 
 
35. Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C et al. Design and 
first baseline data of the DZNE multicenter observational study on predementia 
Alzheimer's disease (DELCODE). Alzheimer's research & therapy 2018; 10(1): 15. 
 
36. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al. Clinical and 
biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 
367(9): 795-804. 
 
Franzmeier et al. 
 
31
37. Franzmeier N, Duzel E, Jessen F, Buerger K, Levin J, Duering M et al. Left frontal 
hub connectivity delays cognitive impairment in autosomal-dominant and sporadic 
Alzheimer's disease. Brain : a journal of neurology 2018. 
 
38. Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, 
Morris JC et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's 
disease occur after amyloid deposition and neuronal injury. Sci Transl Med 2016; 
8(369): 369ra178. 
 
39. Benzinger TL, Blazey T, Jack CR, Jr., Koeppe RA, Su Y, Xiong C et al. Regional 
variability of imaging biomarkers in autosomal dominant Alzheimer's disease. 
Proceedings of the National Academy of Sciences of the United States of America 
2013; 110(47): E4502-4509. 
 
40. Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P et al. 
Cerebrospinal Fluid Abeta42/40 Corresponds Better than Abeta42 to Amyloid PET in 
Alzheimer's Disease. Journal of Alzheimer's disease : JAD 2017; 55(2): 813-822. 
 
41. Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O et 
al. CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of 
Alzheimer disease. Ann Clin Transl Neurol 2016; 3(3): 154-165. 
 
42. Lozoya-Delgado P, Ruiz-Sanchez de Leon JM, Pedrero-Perez EJ. [Validation of a 
cognitive complaints questionnaire for young adults: the relation between subjective 
memory complaints, prefrontal symptoms and perceived stress]. Rev Neurol 2012; 
54(3): 137-150. 




43. Alegret M, Espinosa A, Valero S, Vinyes-Junque G, Ruiz A, Hernandez I et al. Cut-
off scores of a brief neuropsychological battery (NBACE) for Spanish individual 
adults older than 44 years old. PloS one 2013; 8(10): e76436. 
 
44. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G et al. Amyloid 
imaging with (18)F-florbetaben in Alzheimer disease and other dementias. Journal of 
nuclear medicine : official publication, Society of Nuclear Medicine 2011; 52(8): 
1210-1217. 
 
45. Sanabria A, Alegret M, Rodriguez-Gomez O, Valero S, Sotolongo-Grau O, Monte-
Rubio G et al. The Spanish version of Face-Name Associative Memory Exam (S-
FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. 
Scientific reports 2018; 8(1): 3828. 
 
46. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 
189-198. 
 
47. Kent P. The Evolution of the Wechsler Memory Scale: A Selective Review. Appl 
Neuropsychol Adult 2013. 
 
48. Franzmeier N, Caballero MÁA, Taylor ANW, Simon-Vermot L, Buerger K, Ertl-
Wagner B et al. Resting-state global functional connectivity as a biomarker of 
cognitive reserve in mild cognitive impairment. Brain imaging and behavior 2016: 1-
15. 




49. Franzmeier N, Duering M, Weiner M, Dichgans M, Ewers M, Alzheimer's Disease 
Neuroimaging I. Left frontal cortex connectivity underlies cognitive reserve in 
prodromal Alzheimer disease. Neurology 2017; 88(11): 1054-1061. 
 
50. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF et al. 
Brain-derived neurotrophic factor val66met polymorphism affects human memory-
related hippocampal activity and predicts memory performance. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 2003; 23(17): 6690-
6694. 
 
51. Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S et al. Spatial patterns 
of neuroimaging biomarker change in individuals from families with autosomal 
dominant Alzheimer's disease: a longitudinal study. Lancet neurology 2018; 17(3): 
241-250. 
 
52. Araque Caballero MA, Brendel M, Delker A, Ren J, Rominger A, Bartenstein P et al. 
Mapping 3-year changes in gray matter and metabolism in Abeta-positive 
nondemented subjects. Neurobiology of aging 2015; 36(11): 2913-2924. 
 
53. Pasquini L, Scherr M, Tahmasian M, Meng C, Myers NE, Ortner M et al. Link 
between hippocampus' raised local and eased global intrinsic connectivity in AD. 
Alzheimers Dement 2014. 
 
54. Ebeling U, von Cramon D. Topography of the uncinate fascicle and adjacent temporal 
fiber tracts. Acta Neurochir (Wien) 1992; 115(3-4): 143-148. 




55. Von Der Heide RJ, Skipper LM, Klobusicky E, Olson IR. Dissecting the uncinate 
fasciculus: disorders, controversies and a hypothesis. Brain : a journal of neurology 
2013; 136(Pt 6): 1692-1707. 
 
56. Anderson KL, Rajagovindan R, Ghacibeh GA, Meador KJ, Ding M. Theta oscillations 
mediate interaction between prefrontal cortex and medial temporal lobe in human 
memory. Cerebral cortex 2010; 20(7): 1604-1612. 
 
57. Spaniol J, Davidson PS, Kim AS, Han H, Moscovitch M, Grady CL. Event-related 
fMRI studies of episodic encoding and retrieval: meta-analyses using activation 
likelihood estimation. Neuropsychologia 2009; 47(8-9): 1765-1779. 
 
58. Grady CL, McIntosh AR, Craik FI. Age-related differences in the functional 
connectivity of the hippocampus during memory encoding. Hippocampus 2003; 13(5): 
572-586. 
 
59. Axmacher N, Schmitz DP, Wagner T, Elger CE, Fell J. Interactions between medial 
temporal lobe, prefrontal cortex, and inferior temporal regions during visual working 
memory: a combined intracranial EEG and functional magnetic resonance imaging 
study. J Neurosci 2008; 28(29): 7304-7312. 
 
60. Harris AZ, Gordon JA. Long-range neural synchrony in behavior. Annu Rev Neurosci 
2015; 38: 171-194. 
 
Franzmeier et al. 
 
35
61. Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L et al. Changes in hippocampal 
connectivity in the early stages of Alzheimer's disease: evidence from resting state 
fMRI. NeuroImage 2006; 31(2): 496-504. 
 
62. Zhang Y, Simon-Vermot L, Araque Caballero MA, Gesierich B, Taylor AN, Duering 
M et al. Enhanced resting-state functional connectivity between core memory-task 
activation peaks is associated with memory impairment in MCI. Neurobiol Aging 
2016; 45: 43-49. 
 
63. Henseler I, Falkai P, Gruber O. Disturbed functional connectivity within brain 
networks subserving domain-specific subcomponents of working memory in 
schizophrenia: relation to performance and clinical symptoms. J Psychiatr Res 2010; 
44(6): 364-372. 
 
64. Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR et 
al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional 
connectivity in schizophrenia. Arch Gen Psychiatry 2005; 62(4): 379-386. 
 
65. Alvarez-Salvado E, Pallares V, Moreno A, Canals S. Functional MRI of long-term 
potentiation: imaging network plasticity. Philosophical transactions of the Royal 
Society of London Series B, Biological sciences 2014; 369(1633): 20130152. 
 
66. Boots EA, Schultz SA, Clark LR, Racine AM, Darst BF, Koscik RL et al. BDNF 
Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's 
Prevention. Neurology 2017; 88(22): 2098-2106. 
 
Franzmeier et al. 
 
36
67. Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM et al. Decreased 
brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic 
mouse models of Alzheimer's disease. J Neurosci 2009; 29(29): 9321-9329. 
 
68. Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE et al. Cerebrospinal fluid 
concentration of brain-derived neurotrophic factor and cognitive function in non-
demented subjects. PLoS One 2009; 4(5): e5424. 
 
69. Lim YY, Rainey-Smith S, Lim Y, Laws SM, Gupta V, Porter T et al. BDNF 
Val66Met in preclinical Alzheimer's disease is associated with short-term changes in 
episodic memory and hippocampal volume but not serum mBDNF. Int Psychogeriatr 
2017; 29(11): 1825-1834. 
 
70. Krasnow B, Tamm L, Greicius MD, Yang TT, Glover GH, Reiss AL et al. 
Comparison of fMRI activation at 3 and 1.5 T during perceptual, cognitive, and 
affective processing. NeuroImage 2003; 18(4): 813-826. 
 
71. Day GS, Musiek ES, Roe CM, Norton J, Goate AM, Cruchaga C et al. Phenotypic 
Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer 
Disease: A Single-Family Case-Control Study. JAMA neurology 2016; 73(9): 1125-
1132. 
 
72. Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS et al. 
Preferential degradation of cognitive networks differentiates Alzheimer's disease from 
ageing. Brain : a journal of neurology 2018; 141(5): 1486-1500. 
 
Franzmeier et al. 
 
37
73. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM et al. 
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of 
Alzheimer's disease. Alzheimers Res Ther 2011; 3(1): 1. 
 
74. Joshi A, Ringman JM, Lee AS, Juarez KO, Mendez MF. Comparison of clinical 
characteristics between familial and non-familial early onset Alzheimer's disease. J 
Neurol 2012; 259(10): 2182-2188. 
 
75. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M et al. High 
striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease 
mutation types. Archives of neurology 2009; 66(12): 1537-1544. 
 
76. Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H et al. A variant 
of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of 
exon 9 of presenilin 1. Nat Med 1998; 4(4): 452-455. 
 
77. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease 
associated with mutations of the presenilin-1 gene. J Neurol 2006; 253(2): 139-158. 
 
78. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of 
Alzheimer disease-associated neurofibrillary pathology using paraffin sections and 
immunocytochemistry. Acta neuropathologica 2006; 112(4): 389-404. 
 
79. Schultz AP, Chhatwal JP, Hedden T, Mormino EC, Hanseeuw BJ, Sepulcre J et al. 
Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience 
Networks Track with Amyloid and Tau in Clinically Normal Individuals. The Journal 
Franzmeier et al. 
 
38
of neuroscience : the official journal of the Society for Neuroscience 2017; 37(16): 
4323-4331. 
 
80. Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG et 
al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) 
on postmortem brain tissue. Annals of neurology 2015; 78(5): 787-800. 
 
81. Mackay CP, Kuys SS, Brauer SG. The Effect of Aerobic Exercise on Brain-Derived 
Neurotrophic Factor in People with Neurological Disorders: A Systematic Review and 
Meta-Analysis. Neural Plast 2017; 2017: 4716197. 
 
82. Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of 
exercise on synaptic plasticity and cognition. Eur J Neurosci 2004; 20(10): 2580-
2590. 
 
83. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative 
diseases. Nat Rev Neurol 2009; 5(6): 311-322. 
 
   





Table 1: Sample characteristics 





  p-value 
Age 38.97 (10.48) 39.19 (10.67)   0.882 
Gender (f/m) 74/41 56/35   0.678 
BDNFVal66Met 
(Met/Val) 
44/71 24/67   0.071 
Estimated years from 
symptom onset (EYO) 
-7.17 (11.15) -9.03 (11.22)   0.237 
Global PiB-PET 
SUVRa 
1.99 (1.15) 1.07 (0.19)   <0.001 
Aβ-status 
(pos./neg./NA)b  
57/43/15 0/87/4   <0.001 
LM delayed recall 10.29 (6.46) 13.98 (4.12)   <0.001 










Age  67.79 (4.63) 71.46 (5.18) 71.76 (5.53) 74.00 (4.2) <0.001 
Gender (f/m) 30/17 18/21 4/13 8/3 0.014 
BDNFVal66Met 
(Met/Val) 
18/29 15/24 5/12 5/6 0.851 
CSF Aβ42/40 0.1 (0.02) 0.09 (0.03) 0.08 (0.03) 0.05 (0.02) <0.001 
Aβ-status (pos./neg.)c 21/26 25/14 11/6 11/0 0.019 
ApoE4-status 
(pos./neg.) 
10/37 11/28 5/12 8/3 0.010 
LM delayed recall 14.91 (4.46) 13.59 (3.27) 8.41 (6.09) 3.09 (4.41) <0.001 
MMSE 29.55 (0.90) 29.21 (0.92) 27.71 (1.90) 25.00 (4.05) <0.001 
FACEHBI SCD 
(n=149) 
    
Age 65.81 (7.16)     
Gender (f/m) 92/57     
BDNFVal66Met 
(Met/Val) 
67/82     
Global Florbetaben-
PET SUVR 
1.23 (0.14)     
Aβ-status (pos./neg.)d 14/135     
ApoE4-status 
(pos./neg.) 
41/108     
MMSE 29.2 (0.94)     
a = Subsample of 100 MC and 87 NC, b = Aβ positive defined as global PiB-PET SUVR < 1.31, c = 









Table 2: linear models for the interation Amyloid x BDNF on Hippocampal-medial-
frontal connectivity in DELCODE and FACEHBI  
 
 Model terms B/SE T p 
DELCODE-
Hipp-Ra 
CSF Aβ42/40 x BDNFVal66Met -0.404/0.179 -2.261 0.026 
CSF Aβ42/40 0.373/0.156 2.393 0.018 
BDNFVal66Met 0.217/0.184 1.176 0.242 
DELCODE-
Hipp-La 
CSF Aβ42/40 x BDNFVal66Met -0.355/0.169 -2.106 0.037 
CSF Aβ42/40 0.470/0.147 3.195 0.002 
BDNFVal66Met 0.222/0.174 1.270 0.207 
FACEHBI 
Hipp-Rb 
Global Amyloid SUVR x BDNFVal66Met 0.301/0.170 2.040 0.043 
Global Amyloid SUVR -0.186/0.123 -1.455 0.148 
BDNFVal66Met -0.195/0.168 -1.159 0.248 
FACEHBI 
Hipp-Lb 
Global Amyloid SUVR x BDNFVal66Met 0.333/0.195 2.089 0.039 
Global Amyloid SUVR -0.274/0.177 -1.553 0.123 
BDNFVal66Met 0.075/0.167 0.655 0.514 
a=Linear model controlled for age, gender, education, hippocampus volume, diagnosis, 
ApoE4 status and center 
b= Linear model controlled for age, gender, education, hippocampus volume and ApoE4 
status  
Hipp-R = Right Hippocampal-medial-frontal connectivity; Hipp-L = Left Hippocampal-
medial-frontal connectivity   





Figure 1: Surface renderings of significant seed-based connectivity (p<0.001, FWE cluster 
corrected at p<0.05) in the DIAN discovery sample for the primary hippocampal seed ROIs 
and the secondary seed ROIs to derive connectivity for the control network (CON), dorsal 
attention network (DAN), default mode network (DMN) and salience network (SAL). 
 
Figure 2: Results of the voxel-wise interaction analysis of EYO x BDNFVal66Met on 
hippocampal connectivity in the DIAN MC subjects for the left (A&B) and right (E&F) 
hippocampus seed ROI (i.e. discovery). In Panels A&E, red areas correspond to regions 
showing significant seed-based hippocampal connectivity, while purple and blue regions 
indicate the boundaries of the significant EYO x BDNFVal66Met interaction. Validation analyses 
of the BDNFVal66Met x Aβ interaction in DELCODE and FACEHBI using the DIAN MC 
derived medial-frontal ROI are shown in panels C&E for DELCODE and G&H for 
FACEHBI. DIAN-MC = mutation carriers with autosomal dominant AD from DIAN. 
 
Figure 3: Scatterplots illustrating the interaction between right (A-D) and left (E-H) 
hippocampus to medial-frontal connectivity and AD severity (i.e. EYO or CSF Aβ42/40 ratio) 
on cognition. Color groupings were based on median split and are for illustrational purposes 
only, since the underlying linear mixed models were computed using continuous measures. 
DIAN-MC = mutation carriers with autosomal dominant AD from DIAN. 
 



